In Lleida, they sequence almost 100,000 nuclei and redefine carcinosarcomas to better classify their biphasic tissue

A team from the Biomedical Research Institute of Lleida uses single-nucleus sequencing to analyze nearly 100,000 nuclei and clarify the biology of carcinosarcomas.

02 of may of 2026 at 18:00h
In Lleida, they sequence almost 100,000 nuclei and redefine carcinosarcomas to better classify their biphasic tissue
In Lleida, they sequence almost 100,000 nuclei and redefine carcinosarcomas to better classify their biphasic tissue

Xavier Matias-Guiu, from the Biomedical Research Institute of Lleida, has participated in a study that redefines the biological models of carcinosarcomas. The research has been published in The Journal of Pathology and seeks to clarify the nature of this complex tumoral pathology.

Massive sequencing analysis

Belén Pérez-Mies, researcher from the Cancer area of CIBER at the Ramón y Cajal University Hospital, has coordinated this work. The team has employed advanced single-nucleus sequencing technologies to investigate the cellular structure of tumors. The experts have analyzed almost 100,000 cell nuclei in order to understand their internal functioning.

Towards a more precise classification

The findings reveal that biphasic tumors are highly plastic cellular ecosystems. Their origin and differentiation remained unknown, which considerably limited current medical diagnosis. The study uniquely describes the tissue present in these formations and proposes new differentiation programs to classify them precisely.

About the author
Redacción
See biography